Search results
Results from the WOW.Com Content Network
Maropitant (INN; [3] brand name: Cerenia, used as maropitant citrate , is a neurokinin-1 (NK 1) receptor antagonist developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007, for use in dogs [4] [5] and in 2012, for cats. [6]
The chance of side effect can be minimized by administering atipamezole slowly. [12] Atipamezole is sold as Antisedan. There is a possibility of the sedation reversing abruptly, leading to nervous, aggressive, or delirious dogs. [9] Such cases are more associated with intravenous administration [29] (which has a faster onset than IM ...
These drugs, including Oxymorphone, Morphine, Fentanyl, Methadone, Buprenorphine, and Butorphanol, have been highly used in veterinary anesthesia due to their sedative and analgesic properties, despite their side effects. [3] [16] Side effects include respiratory depression, slowing of the digestive tract, and cardiovascular stress.
With collapsing trachea, coughing becomes such a chronic condition that we try to manage it, but it rarely just goes away completely.
Alfaxalone is used as an induction agent, an injectable anesthetic, and a sedative in animals. [5] While it is commonly used in cats and dogs, it has also been successfully used in rabbits, [6] horses, sheep, pigs, and exotics such as red-eared turtles, axolotl, green iguanas, marmosets, [7] and koi fish. [8]
Sedation is the reduction of irritability or agitation by administration of sedative drugs, generally to facilitate a medical procedure or diagnostic procedure. Examples of drugs which can be used for sedation include isoflurane, diethyl ether, propofol, etomidate, ketamine, pentobarbital, lorazepam and midazolam. [1]
Most dogs, however, will need radiation, chemotherapy, and other medications. Even with those therapies, the survival time is short, so ivermectin could help if it proves to be useful.
These side effects are serious and some of them are permanent, and many remain a crucial concern for companies and healthcare professionals and substantial efforts are being encouraged to reduce the potential risks for future antipsychotics through more clinical trials and drug development.